



## Notice of Change of Auditor

**Tokyo, Japan and London, UK, 16 May 2018** – Sosei Group Corporation (“Sosei” or the “Company”; TSE Mothers Index: 4565), the world leader in GPCR medicine design and development, today announced that at a meeting of its Board of Directors held on 15 May 2018, it was resolved to change its certified public accountant responsible for audit certification in accordance with Article 193-2, Paragraphs 1 and 2 of the Financial Instruments and Exchange Act. The details are as follows.

**1. Expected Date of Change**

22 June 2018 (scheduled date of the 28<sup>th</sup> Annual General Meeting of Shareholders)

**2. Overview of the Incoming and Outgoing Auditors**

2.1. Overview of the incoming auditor

Name: Ernst & Young ShinNihon LLC

Location: Hibiya Kokusai Building, 2-2-3 Uchisaiwai-cho, Chiyoda-ku, Tokyo

Names of engagement partners: Hironao Yazaki and Yutaka Mishima

Registration status under the registration system for listed company audit firms of the Japanese Institute of Certified Public Accountants: Registered

2.2. Overview of the outgoing auditor

Name: Deloitte Touche Tohmatsu LLC

Location: Shinagawa Intercity Tower, 2-15-3 Konan, Minato-ku, Tokyo

Names of engagement partners: Shuichi Momoki and Masanori Toyozumi

**3. Reason for Nominating Auditor Stated in 2.1**

The Audit Committee has selected Ernst & Young ShinNihon LLC as the candidate for Accounting Auditor, as it concluded that Ernst & Young ShinNihon LLC is qualified for the role based on a comprehensive review of its auditing systems, including its plans to conduct auditing of the consolidated financial statements on a global basis. Ernst & Young ShinNihon LLC demonstrated significant expertise in quality control systems and has assured independence, and according to our judgment, is well qualified for the position of Accounting Auditor.

**4. Most Recent Date of Appointment of Outgoing Auditor**

22 June 2017

**5. Opinions etc. Stated in Audit Reports, etc. Prepared by the Outgoing Certified Public Accountant in the Immediately Preceding Three Years**

Not applicable

**6. Reasons For and Background to Decision to Make the Change**

Deloitte Touche Tohmatsu LLC, the Accounting Auditor of the Company, will retire at the conclusion of this Ordinary General Meeting of Shareholders. Therefore, the Company would like to propose that the shareholders approve the election of Ernst & Young ShinNihon LLC as Accounting Auditor based on the decision of the Audit Committee.

**7. Opinions of the Outgoing Auditor Concerning the Particulars Stated in Audit Reports and Other Documents Regarding the Reason and Background Described in 6. Above**

The Company received a reply to the effect that there is no particular opinion.

-Ends-



**Enquiries:**

**Sosei Group**

+44 (0) 7912 892 199

Chris Cargill, Head of Investor Relations and Corporate Communications

[ccargill@sosei.com](mailto:ccargill@sosei.com)

**Citigate Dewe Rogerson (for international media)**

+44 (0) 20 7638 9571

David Dible

Mark Swallow

[sosei@citigatedewerogerson.com](mailto:sosei@citigatedewerogerson.com)

**About Sosei**

Sosei is an international biopharmaceutical company focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. The Company is advancing a broad and deep pipeline of partnered and wholly owned product candidates in multiple therapeutic areas, including CNS, cancer, metabolic diseases and other rare/specialty indications. The Company's leading clinical programs include a proprietary Phase 2 candidate for dementia with Lewy bodies (DLB) in Japan, together with partnered candidates aimed at the symptomatic treatment of Alzheimer's disease (with Allergan) and immunology approaches to treat cancer (with AstraZeneca). Sosei's additional partners and collaborators include Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys. The Company is headquartered in Japan with R&D facilities in the UK.

Sosei is listed on the Mothers Index of the Tokyo Stock Exchange (ticker: 4565). For more information, please visit <http://www.sosei.com/en/>.